Clinically, TET2 mutation carriers in AE-Biobank had a two-fold higher prevalence of prior myocardial infarction or stroke compared with non-carriers (23.3% vs 11.1%; P = .13), and a two-fold higher risk of cardiovascular events during follow-up (40.0% vs 20.0%; P = .05) reinforcing the potential role of TET2 CHIP in driving plaque vulnerability and adverse cardiovascular outcomes. The gene discussed is TET2; the disease is stroke disorder.